Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
p53: To Be or Not to Be… Ashim Malhotra Bio 722 Instructor: Dr. Lockshin March, 24, 2003 What is p53? • Tumor suppressor phosphoprotein with 4 domains; Conserved in vertebrates • Gene name: Human: TP53, 17p13.1; Mouse : Trp53 • Gene structure: 19.21 kb; 11 exons • Subcellular Location: Nuclear; in a punctate granular/vesicular patter • Evolution: Xenopus (68% homology) • Sequence comparison: shows 5 highly conserved regions, coinciding with mutation clusters found in p53 in human cancers Why talk of p53? • 27, 458 • Molecule of the Year, Science, 1993 • Guardian of the Genome; Cellular Gatekeeper for Growth & Division (Levine, 1997 review) • Emergency brake in the cell cycle • Bio 722! Involved in PCD What does it do? • Suppresses progression through the cell cycle in response to DNA damage • Initiates apoptosis if the damage to the cell is severe • Often as a tumor suppressor • A potent transcription factor Involvement in diseases; putative applications • p53 gene mutations are the most frequently observed genetic lesions in human cancers • p53 and radiation sensitivity: Problems in radiotherapy • Mutant p53: problems in tumor hypoxia • Gene therapy with p53; Nature 1996 • Clinical Phase trials: (I) Adenovirus vectors expressing p53 in tumors casues regression of mouse lymphomas Come into the mad world of p53… Discovery of p53 The viral approach The serological approach Courtesy: Courtesy: The IARC Human p53 Mutation Database Current release has nearly 7000 entries detailing: • • • • • Location of point mutations Description of mutation Resultant tumor type Exposure information Pointer to original reference article http://www.iarc.fr/p53 Protein structure & DNA binding • Domain: Specific interactions with bcl-2 require ankyrin & SH3 domains • p53 binds as a tetramer to PBS & activates expression of downstream genes inhibiting growth &/or invasion Mechanisms of p53 inactivation 1. 2. 3. 4. 5. p53 binding to PBS. Deletion of one or both p53 alleles= expression of tetramers & expression of the growth inhibitory genes. Nonsense or splice site mutations result in protein-truncation preventing oligomerization reducing tetramers: lung & esophagus. Missense mutations resulting in dominant-negative effects & even greater reduction of functionally active tetramers: colon, brain, lung, breast, skin & bladder. Expression of the HPV - E6 gene causes functional inactivation of p53 through binding and degradation. The p53 pathway may also be disrupted by alteration of a cellular gene, MDM2. p53 Polymorphisms • 2 p53 variants, 1 containing arginine & the other containing proline. • Arginine containing p53 kills cancer cell more effeciently than the one containing proline. • The proline form has an enhanced frequency in African Americans & darker skinned people living closer to the equator!! • Arginine form travels out of the nucleus and into the Mt better than the proline form. Dumont, Leu & Pietra, Nature Genetics, March 2003 What does it do? •Suppresses progression through the cell cycle in response to DNA damage • Initiates apoptosis if the damage to the cell is severe • Often as a tumor suppressor • A potent transcription factor Convergence of distinct stimuli at p53 de Stanchina et al, Genes and Development, 1998 Pathways! Pathways! P on S-15 UV DNA- damage P on S-20 Cytostasis Mdm2 p53 p53 P53 induced cell cycle arrest I N H p53 I p21 B I T I Cyclin-Cdk2 complex Hyp-Rb/E2F complex O N Cytostasis S-20 phosphorylation in response to DNA damage Cheha , Malikzay, Stavridi & Halazonetis. Cell Biology, 1999 Summary of p53 stabilization pathways after DNA damage Giaccia, and Kastan, Genes and Development, 1998 p53 / Rb connection Sherr, Science, 1996 What does it do? •Suppresses progression through the cell cycle in response to DNA damage • Initiates apoptosis if the damage to the cell is severe • Often as a tumor suppressor • A potent transcription factor p53 associated apoptosis • Of 7,202 transcripts identified, only 14 (0.19%) are markedly increased in p53-expressing cells. • Many of these genes encode proteins that generate or respond to oxidative stress. • These observations suggest that p53 causes apoptosis through a three-step process: 1. Transcriptional induction of redox-related genes. 2. Formation of reactive oxygen species and. 3. Oxidative degradation. Polyak, Xia, Zweier, Kinzler & Vogelstein, Nature, 1997. Possible steps in p53 mediated apoptosis: step I UV DNA PK DNA damage p53 DNA PKcs mediates apoptosis but not cytostasis via p53 Wang, Guo ,Ouyang , Li,Cardo ,Kurimasa,Chen,Fuks, Ling , & Li, Cell Biology, 2000 P53! Anoint thee wench! Peg3/PW1 Transcriptional Bax p53 Activation PUMA Bax sublocalization with Peg3 Yibin & Wu, Cell Biology, 2000 Peg3/PW1 causes translocation of Bax to Mitochondria Yibin & Wu, Cell Biology, 2000 Scheme for PUMA induced Mt translocation of Bax PUMA p53 Mt Bcl-Xl Translocation Bax What does it do? •Suppresses progression through the cell cycle in response to DNA damage • Initiates apoptosis if the damage to the cell is severe • Often as a tumor suppressor • A potent transcription factor To P or not to P: c-Myc & p53 p53 C-Myc Miz p53 Inhibits p21/WAF1 Summary • p53, a tumor suppressor, exists as a polymorph & this may be responsible for cancer susceptibility across differing ethnicities. • At a molecular level, it switches cells from cytostasis to apoptosis. • p53 mediated apoptosis occurs via a number of molecular processes: transcriptional upregulation of Bax, hence a change in Bcl2/Bax ratio; of PUMA & Peg3/PW1 & an increase in translocation of Bax to Mt. • p53 cytostasis occurs through the p21/WAF1, Rb pathway. Summary • p53 is being employed for ablation of tumors using gene therapy. • p53 interacts with a number of other proteins, such as JNKs, etc and is involved in a variety of pathways. • P53 offers a profound insight into the working of cancer cells & an opportunity for future therapeutic treatments. Me! Running against time to finish the presentation!